CONNECT BIOPHARMA HOLDINGS LIMITED - AMERICAN DEPO

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

17 июн 2022 15:05:00 Источник Nasdaq GlobeNewswire

Connect Biopharma to Participate at the Jefferies Healthcare Conference

02 июн 2022 15:05:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

17 май 2022 15:05:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

03 май 2022 15:05:01 Источник Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

31 мар 2022 15:05:01 Источник Nasdaq GlobeNewswire

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

01 мар 2022 07:00:15 Источник Nasdaq GlobeNewswire

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

09 фев 2022 06:00:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

24 янв 2022 06:00:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

05 янв 2022 06:00:01 Источник Nasdaq GlobeNewswire

Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201

04 янв 2022 15:05:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

22 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

19 ноя 2021 07:00:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

18 ноя 2021 15:02:00 Источник Nasdaq GlobeNewswire

Connect Biopharma to Participate at Upcoming Conferences

11 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

19 окт 2021 07:00:02 Источник Nasdaq GlobeNewswire

Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps

08 сен 2021 07:00:03 Источник Nasdaq GlobeNewswire

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

31 авг 2021 15:05:00 Источник Nasdaq GlobeNewswire

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

25 авг 2021 07:00:00 Источник Nasdaq GlobeNewswire

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

23 авг 2021 15:05:00 Источник Nasdaq GlobeNewswire